Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 5, Number 3—June 1999
Perspective

Iron Loading and Disease Surveillance

Eugene D. WeinbergComments to Author 
Author affiliation: Indiana University, Bloomington, Indiana, USA

Cite This Article

Abstract

Iron is an oxidant as well as a nutrient for invading microbial and neoplastic cells. Excessive iron in specific tissues and cells (iron loading) promotes development of infection, neoplasia, cardiomyopathy, arthropathy, and various endocrine and possibly neurodegenerative disorders. To contain and detoxify the metal, hosts have evolved an iron withholding defense system, but the system can be compromised by numerous factors. An array of behavioral, medical, and immunologic methods are in place or in development to strengthen iron withholding. Routine screening for iron loading could provide valuable information in epidemiologic, diagnostic, prophylactic, and therapeutic studies of emerging infectious diseases.

Excessive iron in specific tissues (iron loading) promotes infection, neoplasia, cardiomyopathy, arthropathy, and a profusion of endocrine and possibly neurodegenerative disorders (1-5). An array of behavioral, medical, and immunologic methods are being developed to decrease iron loading or its detrimental effects. Routine screening for iron loading in populations exposed to certain diseases can provide valuable epidemiologic, diagnostic, prophylactic, and therapeutic information.

Hazards of Iron Loading

Iron can contribute to disease development in several ways. Excessive amounts of the metal in specific tissues and cells can hinder the ability of proteins, such as transferrin and ferritin, to prevent accretion of free iron. Moreover, in infectious diseases, inflammatory diseases, and illnesses that involve ischemia and reperfusion, iron causes reactions that produce superoxide radicals (6). Nonprotein bound ferric ions are reduced by superoxide, and the ferrous product is reoxidized by peroxide to regenerate ferric ions and yield hydroxyl radicals, which attack all classes of biologic macromolecules. Hydroxyl radicals can depolymerize polysaccharides, cause DNA strand breaks, inactivate enzymes, and initiate lipid peroxidation (6).

Iron can also increase disease risk by functioning as a readily available essential nutrient for invading microbial and neoplastic cells. To survive and replicate in hosts, microbial pathogens must acquire host iron. Highly virulent strains possess exceptionally powerful mechanisms for obtaining host iron from healthy hosts (7). In persons whose tissues and cells contain excessive iron, pathogens can much more readily procure iron from molecules of transferrin that are elevated in iron saturation. In such cases, even microbial strains that are not ordinarily dangerous can cause illness. Markedly invasive neoplastic cell strains can glean host iron more easily than less malignant strains or normal host cells (3). Moreover, iron-loaded tissues are especially susceptible to growth of malignant cells (Table 1).

How Microbes Acquire Iron: A Determinant of Host Range and of Tissue Localization

The number of infectious disease agents whose virulence is enhanced by iron continues to increase (Table 2). To obtain host iron, successful pathogens use one or more of four strategies: binding of ferrated siderophilins with extraction of iron at the cell surface; erythrocyte lysis, digestion of hemoglobin, and heme assimilation; use of siderophores that withdraw iron from transferrin; and procurement of host intracellular iron.

Microbial strains that use siderophilin binding often have a very narrow host range (7). Bacterial receptors recognize siderophilins generally from a single or closely related host species. Strains of Haemophilus somnus, for example, form receptors for bovine but not for human transferrin; these bacteria are virulent for cattle but not for humans (9). The human pathogen, Neisseria meningitidis, can bind ferrated transferrins from humans and such hominids as chimpanzees, gorillas, and orangutans, but not from monkeys or nonprimate mammals (10,11). Actinobacillus pleuropneumoniae synthesizes a swine-specific transferrin receptor and causes pneumonia only in hogs (12).

Each of the above three pathogens, as well as other organisms that use siderophilin binding, can often obtain iron from heme. Helicobacter pylori, for instance, first obtains iron from human ferrated lactoferrin in the gastric lumen. Then, as it migrates into intercellular junctions of epithelial cells in the gastric wall, its sole source of iron is heme. This pathogen binds neither bovine ferrated lactoferrin nor human, bovine, or equine ferrated transferrin (13).

However, not every pathogen that uses siderophilin binding has a narrow host range. For example, Staphylococcus aureus can be virulent for a variety of mammalian species. Strains of this organism can bind human, rat, and rabbit transferrins and, much less efficiently, bovine, porcine, and avian transferrins (14). Moreover, isolates of S. aureus also may produce siderophores (15,16). These small molecules can withdraw iron from transferrins synthesized by a variety of host species. The siderophore, staphyloferrin A, removes iron from both human and porcine transferrin; thus, the metal can be available to invading cells in humans and in hogs. Erythrocyte lysis, digestion of hemoglobin, and heme assimilation are available to strains of S. aureus. Bacterial hemolysins generally are active against erythrocytes from several, although not from all, potential host species.

Virulent streptococci are examples of bacteria that neither bind siderophilins nor produce siderophores yet proficiently invade and replicate in many tissues in diverse host species. The cellulytic activities of these pathogens enable them to access such intracellular sources of host iron as hemoglobin, myoglobin, catalase, and ferritin (17).

The remarkable versatility for host species shown by Listeria monocytogenes illustrates the adeptness of this organism in procuring iron. Although mainly a saprophyte that lives in the plant-soil environment, L. monocytogenes can be acquired by humans and other mammals through ingestion of undercooked tissue of other mammals, birds, fish, and Crustacea, as well as from raw vegetables. Unable to bind siderophilins or form siderophores, L. monocytogenes obtains iron by using either exogenous siderophores of other microorganisms or natural catechols, such as dopamine and norepinephrine, in host tissues. The pathogen expresses a cell surface ferric reductase that recognizes the siderophoric chelated iron site; the metal is then reduced and assimilated (18). Furthermore, in contrast to saprophytic strains, systemic pathogenic strains of L. monocytogenes are hemolytic.

To grow within host cells, pathogens apparently are not required to synthesize siderophilin binding sites or form siderophores. For instance, unlike the wild type, siderophore-minus mutants of Salmonella Typhimurium cannot grow in extracellular compartments of the host. However, both the wild and mutant strains replicate within host cells (19). Possible sources of intracellular iron are heme, iron released from transferrin at pH 5.5-6, and ferritin.

For at least two pathogens, Francisella tularensis and Legionella pneumophila, the host intracellular niche is obligatory. Like the mutant strain of S. Typhimurium, these organisms are unable to access iron in extracellular fluids and tissues. Culturing these bacteria in laboratory media requires markedly elevated concentrations of iron (20,21).

In host intracellular niches, growth of microbial pathogens is stimulated by elevation and depressed by decrease of iron. Indeed, at least one bacterial pathogen, Ehrlichia chaffeensis, induces elevation of iron in its host cells; intracellular inclusions of the organism cause the host cell to upregulate expression of the transferrin receptor mRNA (22).

Iron Withholding Defense System

Hosts use several mechanisms (Table 3) to withhold iron from invading microbial and neoplastic cells: stationing of potent iron binding proteins at sites of impending microbial invasion; lowering iron levels in body fluids, diseased tissues, and invaded cells during invasion; and synthesizing immunoglobulins to the iron acquisition antigens of microbes.

High concentrations of iron not only benefit invading cells, they may also mediate antimicrobial activities of defense cells. In in vitro studies, 150 µM iron augmented macrophage killing of Brucella abortus (24) and, without altering phagocytosis, 250 µM iron enhanced anti-Candida activity of microglia (25). In the latter system, the metal suppressed synthesis of nitric oxide but not of tumor necrosis factor A. By generating oxidant-sensitive mediators, iron may focus influx of neutrophils to sites of infection (26). Iron loading of staphylococci increased their killing by peroxide, macrophages, and neutrophil-derived cytoplasts but not by neutrophils (27). Certain conditions can impair iron withholding (Table 4); numerous studies have presented evidence that risk for infection or neoplasia is increased significantly in persons with these conditions.

Detection of Iron Loading

Screening of large populations for iron loading can be accomplished with inexpensive, noninvasive methods. A useful indicator of iron loading is marked elevation of serum ferritin (sFt). However, sole reliance on this measurement can be misleading because sFt increases moderately during inflammatory episodes. Accordingly, concurrent determination of the percentage of iron saturation of serum transferrin (%TS) provides useful information (29). In iron loaded persons, hyperferritinemia generally is accompanied by an elevation in %TS. In contrast, in patients with an inflammatory process, hyperferritinemia generally is accompanied by a reduction in %TS.

Iron loading is associated also with moderate depression of a third variable, serum transferrin receptor (sTfR). The ratio of sTfR/sFt, apparently independent of inflammation, is significantly reduced in persons with high levels of iron (5).

Strengthening the Iron Withholding Defense

A considerable array of behavioral, medical, and immunologic methods are in place or in development for strengthening iron withholding (Table 5) (3). Additional precautions are indicated for persons who are known to be (or have a tendency to become) iron loaded. For example, persons with elevated iron due to either hemochromatosis or alcoholism are cautioned to avoid eating raw oysters, which may contain Vibrio vulnificus (30). Another pathogen that likewise causes severe systemic infection in hosts with elevated iron is Capnocytophaga canimorsis. Accordingly, persons who have hemochromatosis, alcoholism, or asplenia are advised to receive prompt antibiotic therapy if they are exposed to a dog bite (31).

De-ironing by phlebotomy is effective in lowering risk for cardiovascular diseases (32,33) and various neoplasms (34), as well as in therapy for hepatitis C (35). Interfering with iron metabolism by administering gallium can be useful in suppressing growth of lymphoma and bladder cancer cells (36). The antineoplastic action of monoclonal antibodies against ferrated transferrin receptors has been examined (37). Combinations of the iron chelator, deferoxamine, with gallium or with antibodies against ferrated transferrin receptors increase effectiveness against tumor cells.

The natural iron scavenger, lactoferrin, has been shown to remove free iron from synovial fluid aspirated from joints of rheumatoid arthritic patients (38). Recombinant human lactoferrin, which is indistinguishable from native breast milk lactoferrin with respect to its iron binding properties, is now available (39) and could become a very useful addition to our array of de-ironing pharmaceutical products.

A recently discovered integral membrane phosphoglycoprotein, Nrampl, is expressed exclusively in macrophages and is localized to phagolysosomes. The protein suppresses replication of intramacrophage microbial invaders apparently by altering iron availability (23). A second protein, Nramp2, is involved in enhancement of intestinal iron absorption (40). Future research might develop useful medical procedures for modulation of the actions of these proteins.

Potential vaccines that incorporate iron acquisition antigens of pathogens in the families Neisseriaceae and Pasteurellaceae are being developed by several research groups. For example, in Moraxella catarrhalis, the recombinant transferrin binding protein B (TbpB) has been shown to elicit bactericidal antibodies (41) In N. meningitidis, antisera to TbpA and TbpB were bactericidal for both homologous and heterologous strains (42,43). Because the antigenic proteins function at the cell surfaces of the pathogens, the receptors are potentially ideal vaccine candidates. For synthesis of the receptors, the organisms must be cultured in iron-restricted media.

Perspectives and Conclusions

There is growing awareness that transmissible agents are involved in diseases not earlier suspected of being infectious (44-46). A recent review contains a list of 34 degenerative, inflammatory, and neoplastic diseases associated in various ways with specific infectious agents (44). Other chronic inflammatory diseases, such as sarcoidosis, inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, Wegener granulomatosis, diabetes mellitus, primary biliary cirrhosis, tropical sprue, and Kawasaki disease may also have infectious etiologies (45). Excessive iron is correlated with synovial damage in rheumatoid arthritis (47) and with impaired glucose metabolism in diabetes (48). The association of Chlamydia pneumoniae (49) and excessive iron (5) with cardiovascular disease is well established. Growth of this pathogen is strongly suppressed by iron restriction (50).

Proving the role of infection in chronic inflammatory diseases and cancer presents challenges (46). The means by which pathogens suppress, subvert, or evade host defenses to establish chronic or latent infection have received little attention. However, the association and causal role of infectious agents in chronic inflammatory diseases and cancer have major implications for public health, treatment, and prevention (44-46).

Iron loading is a risk factor in these illnesses, as well as in classic infectious diseases. Because the prevalence of iron loading in various populations can be remarkably high, routine screening of iron values in host populations could provide valuable information in epidemiologic, diagnostic, prophylactic, and therapeutic studies of emerging infectious diseases.

Dr. Weinberg is professor emeritus of microbiology in both the College of Arts and Sciences and the School of Medicine at Indiana University, Bloomington, IN. His studies on iron were initiated in 1952. Since retiring from teaching in 1992, he has devoted full time to research.

Top

Acknowledgments

Dedicated to Jerome L. Sullivan, pioneer and leader in our awareness of the role of iron in cardiovascular disease.

Support for this review was provided by the Office of Research and the University Graduate School, Indiana University, Bloomington, IN, USA.

Top

References

  1. Kontoghiorghes  GJ, Weinberg  ED. Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches. Blood Rev. 1995;9:3345. DOIPubMedGoogle Scholar
  2. Weinberg  ED, Weinberg  GA. The role of iron in infection. Curr Opin Infect Dis. 1995;8:1649. DOIGoogle Scholar
  3. Weinberg  ED. The role of iron in cancer. Eur J Cancer Prev. 1996;5:1936.PubMedGoogle Scholar
  4. Connor  JR, Beard  JL. Dietary iron supplements in the elderly: to use or not to use? Nutr Today. 1997;32:1029. DOIGoogle Scholar
  5. Tuomainen  T-P, Punnonen  K, Nyyssonen  K, Salonen  JT. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation. 1998;97:14616.PubMedGoogle Scholar
  6. McCord  JM. Effects of positive iron status at a cellular level. Nutr Rev. 1996;54:858.PubMedGoogle Scholar
  7. Weinberg  ED. Patho-ecological implications of microbial acquisition of host iron. Reviews in Medical Microbiology. 1998;9:1718.
  8. Weinberg  ED. Acquisition of iron and other nutrients in vivo. In: Roth JA, Bolin CA, Brogdon KA, Wannemuehler MJ, editors. Virulence mechanisms of bacterial pathogens. Washington: American Society for Microbiology; 1995. p. 79-94.
  9. Ogunnariwo  JA, Cheng  C, Ford  J, Schryvers  AB. Response of Haemophilus somnus to iron limitation: expression and identification of a bovine-specific transferrin receptor. Microb Pathog. 1990;9:397406. DOIPubMedGoogle Scholar
  10. Arko  RJ. Animal models for Neisseria species. Clin Microbiol Rev. 1989;2:S569.PubMedGoogle Scholar
  11. Gray-Owen  SD, Schryvers  AB. The interaction of primate transferrins with receptors on bacteria pathogenic to humans. Microb Pathog. 1993;14:38998. DOIPubMedGoogle Scholar
  12. Gonzalez  GC, Casmano  OL, Schryvers  AB. Identification and characterization of a porcine-specific transferrin receptor in Actinobacillus pleuropneumoniae. Mol Microbiol. 1990;4:11739. DOIPubMedGoogle Scholar
  13. Worst  DJ. Iron acquisition by Helicobacter pylori. Ph.D. thesis. Amsterdam: Vrije Universiteit; 1997; p. 109-16.
  14. Modun  B, Evans  RW, Joannou  CL, Williams  P. Receptor-mediated recognition and uptake of iron from human transferrin by Staphylococcus aureus and Staphylococcus epidermidis. Infect Immun. 1998;65:19448.
  15. Lindsay  JA, Riley  TV. Staphylococcal iron requirements, siderophore production, and iron-regulated protein expression. Infect Immun. 1994;62:230914.PubMedGoogle Scholar
  16. Courcol  RJ, Trivier  D, Bissinger  M-C, Martin  GR, Brown  MRW. Siderophore production by Staphylococcus aureus and identification of iron-regulated proteins. Infect Immun. 1997;65:19448.PubMedGoogle Scholar
  17. Eichenbaum  Z, Muller  E, Morse  SA, Scott  JR. Acquisition of iron from host proteins by the group A streptococcus. Infect Immun. 1996;64:54289.PubMedGoogle Scholar
  18. Coulanges  V, Andre  P, Vidon  DJ-M. Effect of siderophores, catecholamines, and catechol compounds on Listeria spp. growth in iron-complexed medium. Biochem Biophys Res Commun. 1998;24:52630. DOIGoogle Scholar
  19. Tsolis  RM, Baumler  AJ, Heffron  F, Stojikovic  I. Contributions of TonB- and feo-mediated iron uptake to growth of Salmonella typhimurium in the mouse. Infect Immun. 1996;64:454956.PubMedGoogle Scholar
  20. Fortier  AH, Leiby  DA, Narayanan  RB, Asafoadjei  E, Crawford  RM, Nacy  CA, . Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infect Immun. 1995;63:147883.PubMedGoogle Scholar
  21. Byrd  TF. Cytokines and legionellosis. Biotherapy. 1994;7:17986. DOIPubMedGoogle Scholar
  22. Barnewall  RE, Rikihisa  Y, Lee  EH. Ehrlichia chaffeensis inclusions are early endosomes which selectively accumulate transferrin receptor. Infect Immun. 1997;65:145561.PubMedGoogle Scholar
  23. Gomes  MS, Appelberg  R. Evidence for a link between iron metabolism and Nrampl gene function in innate resistance against Mycobacterium avium. Immunology. 1998;95:1658. DOIPubMedGoogle Scholar
  24. Jiang  X, Baldwin  CL. Iron augments macrophage-mediated killing of Brucella abortus alone and in conjunction with interferon. Cell Immunol. 1993;148:397407. DOIPubMedGoogle Scholar
  25. Saleppico  S, Mazzolla  R, Boelaert  JR, Puliti  M, Barluzzi  R, Bistoni  F, Iron regulates microglial cell-mediated secretory and effector functions. Cell Immunol. 1996;170:2519. DOIPubMedGoogle Scholar
  26. Ghio  AJ, Piantadosi  CA, Crumbliss  AL. Hypothesis: iron chelation plays a vital role in neutrophilic inflammation. Biometals. 1997;19:13542. DOIGoogle Scholar
  27. Hoepelman  IM, Bezemer  WA, Vandenbroucke-Grauls  CMJE, Marx  JJM, Verhoef  J. Bacterial iron enhances oxygen radical-mediated killing of Staphylococcus aureus by phagocytes. Infect Immun. 1990;58:2631.PubMedGoogle Scholar
  28. Delanghe  JR, Langlois  MR, Boelaert  Jr, Van Acker  J, Van Wanzeele  F, van der Groen  G, . Haptoglobin polymorphism, iron metabolism and mortality in HIV infection. AIDS. 1998;12:102732. DOIPubMedGoogle Scholar
  29. Witte  DL, Crosby  WH, Edwards  CQ, Fairbanks  VF, Mitros  FA. Hereditary hemochromatosis. Clin Chim Acta. 1996;245:139200. DOIPubMedGoogle Scholar
  30. Shapiro  RL, Altekruse  S, Hutwagner  L, Bishop  R, Hammond  R, Wilson  S, The role of Gulf Coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988-1996. J Infect Dis. 1998;178:7529. DOIPubMedGoogle Scholar
  31. Weinberg  ED. DF-2 sepsis: a sequela of sideremia? Med Hypotheses. 1987;24:2879. DOIPubMedGoogle Scholar
  32. Meyers  DG, Strickland  D, Maloley  PA, Seburg  JK, Wilson  JE, McManus  BF. Possible association of a reduction in cardiovascular events with blood donation. Heart. 1997;78:18893.PubMedGoogle Scholar
  33. Kiechl  S, Willeit  J, Egger  G, Poewe  W, Oberhollenzer  F. Body iron stores and the risk of carotid atherosclerosis. Prospective results from the Bruuneck study. Circulation. 1997;96:33007.PubMedGoogle Scholar
  34. Merk  K, Mattson  B, Mattson  A, Holm  G, Gullbring  B, Bjorkholm  M. The incidence of cancer among blood donors. Int J Epidemiol. 1990;19:5059. DOIPubMedGoogle Scholar
  35. Bonkovsky  HL, Banner  BF, Rothman  AL. Iron and chronic viral hepatitis. Hepatology. 1997;26:75968. DOIGoogle Scholar
  36. Chitambar  CR, Narasimhan  J. Targeting iron-dependent DNA synthesis with gallium and transferrin-gallium. Pathobiology. 1991;59:310. DOIPubMedGoogle Scholar
  37. Kemp  JD. Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. Histol Histopathol. 1997;12:2916.PubMedGoogle Scholar
  38. Guillen  C, McInnes  IB, Kruger  H, Brock  JH. Iron, lactoferrin-and iron regulatory protein activity in the synovium; relative importance of iron loading and the inflammatory response. Ann Rheum Dis. 1998;57:30914. DOIPubMedGoogle Scholar
  39. Ward  PP, Piddington  CS, Cunningham  GA, Zhou  X, Wyatt  RD, Conneely  OM. A system for production of commercial quantities of human lactoferrin, a broad spectrum natural antibiotic. Biotechnology. 1995;13:498503. DOIPubMedGoogle Scholar
  40. Andrews  NC, Levy  JE. Iron is hot: an update on the pathophysiology of hemochromatosis. Blood. 1998;92:184551.PubMedGoogle Scholar
  41. Myers  LE, Yang  Y-P, Du  R-P, Wang  Q, Harkness  RE, Schryvers  AB, The transferrin binding protein B of Moraxella catarrhalis elicits bactericidal antibodies and is a potential vaccine antigen. Infect Immun. 1998;66:418392.PubMedGoogle Scholar
  42. Lissolo  L, Maitre-Wilmotte  G, Dumas  P, Mignon  M, Danve  B. QuentinMillet M-J. Evaluation of transferrin-binding protein 2 within the transferrin-binding complex as a potential antigen for future meningococcal vaccines. Infect Immun. 1995;63:88490.PubMedGoogle Scholar
  43. Pintor  M, Ferron  L, Gomez  JA, Powell  NBL, Ala `Aldeen  DAA, Boriello  SP, . Blocking of iron uptake from transferrin by antibodies against the transferrin binding proteins in Neisseria meningitidis. Microb Pathog. 1996;20:12739. DOIPubMedGoogle Scholar
  44. Lorber  B. Are all diseases infectious? Ann Intern Med. 1996;125:84451.PubMedGoogle Scholar
  45. Relman  DA. Detection and identification of previously unrecognized microbial pathogens. Emerg Infect Dis. 1998;4:3829. DOIPubMedGoogle Scholar
  46. Cassell  GH. Infectious causes of chronic inflammatory diseases and cancer. Emerg Infect Dis. 1998;4:47587. DOIPubMedGoogle Scholar
  47. Morris  CJ, Earl  JR, Trenam  CW, Bkaje  DR. Reactive oxygen species and irona dangerous partnership in inflammation. Int J Biochem Cell Biol. 1995;27:10922. DOIPubMedGoogle Scholar
  48. Tuomainen  T-P, Nyyssonen  K, Salonen  R, Tervahauta  A, Korpela  H, Lakka  T, Body iron stores are associated with serum insulin and blood glucose concentrations. Diabetes Care. 1997;20:4268. DOIPubMedGoogle Scholar
  49. Campbell  LA, Kuo  C-C, Grayston  JT. Chlamydia pneumoniae and cardiovascular disease. Emerg Infect Dis. 1998;4:5719. DOIPubMedGoogle Scholar
  50. Freidank  HM, Billing  H. Influence of iron restriction on the growth of Chlamydia pneumoniae TWAR and Chlamydia trachomatis. Clinical Microbiology and Infection 1997;3 Suppl 2:193.23

Top

Tables

Top

Cite This Article

DOI: 10.3201/eid0503.990305

Table of Contents – Volume 5, Number 3—June 1999

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

E.D. Weinberg, Jordan Hall 142, Indiana University, Bloomington, IN 47405, USA; fax: 812-855-6705

Send To

10000 character(s) remaining.

Top

Page created: December 10, 2010
Page updated: December 10, 2010
Page reviewed: December 10, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external